cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

Conditions: Locally Advanced Head and Neck Carcinoma

Sex: All

Ages: 18 Years – 80 Years

Healthy volunteers: No

Phase: NA

Enrollment: 59

Sponsor: Centre Jean Perrin

Location: Centre Jean PERRIN Clermont-Ferrand Puy-de-Dôme

Summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma. The main question it aims to answer is : \- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological). Participants will : * be included in the main study (Neck-TAR) * have a blood sample 1 and 3-month after the end of treatment

Eligibility Criteria

Selection Criteria: * Patient included in NeckTAR study * Written informed consent signed for NeckTAR-IN study * Affiliation to the French social security system

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07178847). StuddyBuddy aggregates publicly available trial information.